Skip to main content

Table 5 Univariate analyses of prognostic factors for disease-free survival and overall survival in patients with stage III colon cancer who received curative treatment

From: Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Variables Disease-free survival Overall survival
HR (95% CI) P value HR (95% CI) P value
Age, year (> 60 vs. ≤ 60)) 1.702
(1.057–2.702)
0.026 1.465
(0.778–2.758)
0.237
Gender (male vs. female) 1.891
(1.132–3.159)
0.015 1.877
(0.954–3.693)
0.068
BMI, kg/m2 (< 18.5 vs. ≥ 18.5) 1.725
(0.538–5.527)
0.036 0.775
(0.274–2.191)
0.630
Tumor size, cm (> 4 vs. ≤ 4) 0.781
(0.483–1.264)
0.314 0.962
(0.516–1.794)
0.902
Tumor location
(right-sided colon vs. left-sided colon)
0.798
(0.496–1.285)
0.353 0.400
(0.213–1.754)
0.557
Differentiation
(poor vs. well/moderately differentiated)
1.354
(0.815–2.248)
0.242 1.245
(0.632–2.451)
0.527
T stage (T4 vs. T1–3) 1.446
(0.895–2.337)
0.132 2.311
(1.170–4.564)
0.016
Numbers of resected lymph nodes
(< 12 vs. ≥ 12)
1.356
(0.817–2.250)
0.239 0.938
(0.458–1.919)
0.860
N stage (N2 vs. N1) 1.334
(0.813–2.190)
0.225 1.817
(0.971–3.403)
0.062
Preoperative serum CEA, ng/mL
(> 5 vs. ≤ 5)
1.721
(1.072–2.760)
0.024 1.104
(0.590–2.067)
0.757
Preoperative serum CA19-9, U/mL
(> 24 vs. ≤ 24)
2.674
(1.667–4.288)
< 0.001 2.216
(1.190–4.124)
0.012
Risk stratification (high vs. l ow) 1.262
(0.764–2.086)
0.363 2.441
(1.122–5.313)
0.024
Adjuvant chemotherapy
(unfinished XELOX vs. modified XELOX)
1.668
(1.010–3.057)
0.043 3.256
(1.305–8.126)
0.011
Adjuvant chemotherapy
(standard XELOX vs. modified XELOX)
0.935
(0.489–1.785)
0.838 0.551
(0.207–1.468)
0.233
  1. XELOX oxaliplatin, and capecitabine regimen, BMI body mass index, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, HR hazard ratio, CI confidence interval
  2. Right-sided colon cancer included the cecum, ascending colon, hepatic flexure, and transverse colon cancer, whereas left-sided colon cancer included the splenic flexure, descending colon, and sigmoid colon cancer